文献速递其他结缔组织病

系统性硬化症肌肉受累:高死亡率与组织学病变性质无关

Muscle involvement in systemic sclerosis: high mortality not associated with nature of histological lesions.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该多中心回顾性研究纳入71例经肌肉活检证实肌肉受累的系统性硬化症患者,按组织学分为纤维性肌病、炎性肌病和免疫介导坏死性肌病三组,比较生存率、肌肉复发及心肺事件。随访中位6.4年,21例死亡,10年生存率80%,肌肉复发累积发生率25%,两组结局在三组间无显著差异;炎性肌病组肺部事件风险显著低于纤维性肌病组(HR 0.17,95%CI 0.04-0.67)。结论认为肌肉受累患者死亡率与组织学模式无关。

要点

  • 71例系统性硬化症肌肉活检患者中,纤维性肌病占46.5%,炎性肌病占25.5%,坏死性肌病占28%。
  • 随访中位6.4年,21例死亡,10年生存率80%,肌肉复发累积发生率25%,三组间无显著差异。
  • 炎性肌病组肺部事件风险显著低于纤维性肌病组(HR 0.17,95%CI 0.04-0.67),心脏事件三组无显著差异。

核心结论

  • 系统性硬化症合并肌肉受累患者的死亡率与组织学病变模式无关。

研究设计与样本

  • 多中心回顾性研究,纳入71例经肌肉活检证实肌肉受累的系统性硬化症患者,按组织学分为纤维性肌病、炎性肌病和免疫介导坏死性肌病三组。

主要发现

  • 71例中纤维性肌病33例(46.5%),炎性肌病18例(25.5%),坏死性肌病20例(28%)。
  • 随访中位6.4年(四分位距2.2-10.9年),21例死亡,主要死于心脏病和感染。
  • 首次非雷诺现象症状后10年生存率80%,肌肉复发累积发生率25%,两者在三组间无显著差异。
  • 炎性肌病组肺部事件风险显著低于纤维性肌病组(HR 0.17,95%CI 0.04-0.67),较坏死性肌病组非显著降低(HR 0.28,95%CI 0.06-1.24)。
  • 心脏事件风险在三组间无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to determine the association between various histological patterns and prognosis in patients with SSc and histologically proven muscle involvement. METHODS: A multicentre retrospective study was conducted of a cohort of scleroderma patients who had undergone muscle biopsy. The biopsies were reviewed in a coordinated manner to classify patients based on the histological findings. Three different patterns were observed: fibrosing myopathy (FMy), inflammatory myopathy (IMy), and immune-mediated necrotizing myopathy (IMNMy). Rates of survival, muscle relapse, and cardiac and pulmonary events were compared between these three groups. RESULTS: Among the 71 scleroderma patients with muscle biopsy specimens available for review, 33 (46.5%) were classified in the FMy group, 18 (25.5%) in the IMy group and 20 (28%) in the NMy group. The median follow-up time was 6.4 years (interquartile range, 2.2-10.9 years), and 21 patients died during follow-up, primarily from heart disease and infections. The 10-year survival rate after the first non-RP symptom was 80%, and the cumulative incidence of muscle relapse was 25%. Neither factor differed significantly between the three groups. The risk of pulmonary events was lowest in the IMy group, significantly lower than in the FMy group (hazard ratio, 0.17; 95% CI, 0.04-0.67) and non-significantly lower than in the IMNMy group (hazard ratio, 0.28; 95% CI, 0.06-1.24). The risk of cardiac events did not differ significantly between the three groups. CONCLUSION: The mortality rate in scleroderma patients with muscle involvement was not associated with their histological patterns.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Le Gouellec N, Zaidan L, Chaigne B, et al. Muscle involvement in systemic sclerosis: high mortality not associated with nature of histological lesions. Rheumatology (Oxford). 2025. PMID: 39137158. doi:10.1093/rheumatology/keae407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。